<!DOCTYPE html>
<html lang="en">
<head>
  
  
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    
    <link rel="canonical" href="https://jzpero.github.io/mednotes/Critical%20Care/Shock%20and%20Resuscitation/Inotropes/">
    <link rel="shortcut icon" href="../../../img/favicon.ico">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
    <title>Inotropes - MedNotes</title>
    <link href="../../../css/bootstrap-3.3.7.min.css" rel="stylesheet">
    <link href="../../../css/font-awesome-4.7.0.css" rel="stylesheet">
    <link href="../../../css/base.css" rel="stylesheet">
    <link rel="stylesheet" href="../../../css/highlight.css">
    <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <script src="../../../js/jquery-3.2.1.min.js"></script>
    <script src="../../../js/bootstrap-3.3.7.min.js"></script>
    <script src="../../../js/highlight.pack.js"></script>
    
    <base target="_top">
    <script>
      var base_url = '../../..';
      var is_top_frame = false;
        
        var pageToc = [
          {title: "Inotropes", url: "#_top", children: [
              {title: "Background", url: "#background" },
              {title: "Dobutamine", url: "#dobutamine" },
              {title: "Milrinone", url: "#milrinone" },
              {title: "Isoproterenol", url: "#isoproterenol" },
              {title: "Dopamine", url: "#dopamine" },
              {title: "Levosimendan", url: "#levosimendan" },
              {title: "Evidence Base", url: "#evidence-base" },
              {title: "References", url: "#references" },
          ]},
        ];

    </script>
    <script src="../../../js/base.js"></script> 
</head>

<body>
<script>
if (is_top_frame) { $('body').addClass('wm-top-page'); }
</script>



<div class="container-fluid wm-page-content">
  <a name="_top"></a>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Massive%20Transfusion/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Massive%20Transfusion/" class="btn btn-xs btn-link">
        Massive Transfusion
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Fluid%20Responsiveness/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Fluid%20Responsiveness/" class="btn btn-xs btn-link">
        Fluid Responsiveness
      </a>
    </div>
    
  </div>

    

    <h1 id="inotropes">Inotropes</h1>
<h2 id="background">Background</h2>
<h3 id="indications">Indications</h3>
<p>Intotropes are indicated for patients with LV systolic dysfunction, low CO, and low SBP (e.g. &lt; 90 mmHg) resulting in end organ hypoperfusion (<em>i.e. cardiogenic shock</em>).
-   Short term hemodynamic support
-   Bridge therapy to MCS/<a href="../../ECLS/">ECLS</a>/Transplant
-   Limited use in long-term hemodynamic support</p>
<h3 id="caution">Caution</h3>
<p>Inotropes can cause sinus tachycardia, increase RVR in AF (increased AVN conduction), induce myocardial ischemia and arrythmias, and increase mortality.</p>
<h3 id="inotropic-agents">Inotropic Agents</h3>
<table>
<thead>
<tr>
<th>Agent</th>
<th>Class</th>
<th>MOA</th>
<th>Dosing</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dobutamine</td>
<td>Beta agonist (synthetic)</td>
<td>B1/B2 agonist. Variable A1 activity.</td>
<td>2-20 mcg/kg/min</td>
<td></td>
</tr>
<tr>
<td>Dopamine</td>
<td>Beta agonist (endogenous)</td>
<td>Dose-dependent delta-&gt;beta-&gt;alpha affects. Introtropy, arteriovenous constriction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isoproterenol</td>
<td>Nonselective beta agonist</td>
<td>Beta 1/2 agonism.</td>
<td>2-10 mcg/min</td>
<td>Used for bradyarrhythmias (especially TdP), Brugade syndrome</td>
</tr>
<tr>
<td>Milrinone</td>
<td>PDE inhibitor</td>
<td>PDE-3 inhibitor, decreases cAMP degradation distally to beta receptor. Increases Ca++ influx to cell. Vasodilation via vascular PDE inhibition.</td>
<td>0.375–0.75 mcg/kg/min</td>
<td></td>
</tr>
<tr>
<td>Levosimendan</td>
<td>Ca-sensitizing agent</td>
<td>Increases myocardial contraction with Ca++. PDE-3 inhibition.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="specific-use-cases">Specific Use Cases</h3>
<table>
<thead>
<tr>
<th>Setting</th>
<th>Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypotension</td>
<td>Dobutamine preferred over PDE-3 inhibitors or Ca-sensitizing agents due to less vasodilatory effects.</td>
</tr>
<tr>
<td>Renal insufficiency</td>
<td>Dobutamine preferred to milrinone. Dose adjustment necessary with milrinone.</td>
</tr>
<tr>
<td>Recent beta-blockade</td>
<td>PDE-3 inhibitor preferred due to different MOA. Alternatively, use high-dose dobutamine.</td>
</tr>
<tr>
<td>AFRVR</td>
<td>Avoid dobutamine and dopamine if possible.</td>
</tr>
</tbody>
</table>
<h2 id="dobutamine">Dobutamine</h2>
<p>Dobutamine is a synthetic catecholamine that acts as a β1- and β2-receptor agonist.</p>
<ul>
<li>binds β1:β2 at a 3:1 ratio, therefore is a potent inotrope with weaker chronotropic effect</li>
<li>vascular smooth muscle binding and β2 stimulation lead to mild vasodilation, particularly at lower doses (&lt;5 mcg/kg/min). This effect is ameliorated at higher doses where vasoconstriction dominates</li>
<li><strong>increases myocardial oxygen consumption significantly</strong> despite its mild chronic effects at low-medium doses. "Exercise-mimicking effect" makes it also useful for diagnostic cardiac perfusion imaging. </li>
<li><strong>risk of malignant ventricular arrhythmias</strong> can be observed at any dose</li>
<li>rare risk of <strong>hypersensitivity myocarditis</strong> (eosinophilic) in 2-20% of patients. Dose-dependent risk.</li>
</ul>
<h2 id="milrinone">Milrinone</h2>
<p>Milrinone is a phosphodiesterase 3 inhibitor that increases cardiac inotropy, lusitropy, and peripheral vasodilatation. Preference is often given to using milrinone in patients with severe <a href="../../../Respirology/Pulmonary%20Hypertension/">pulmonary hypertension</a> because of a purported mechanism of reducing pulmonary-artery pressures and improving right ventricular function.</p>
<ul>
<li>Causes hypotension - avoid a loading dose.</li>
<li>Avoid in <a href="../../../Cardiology/Ischemic%20Heart%20Disease/Chronic%20Coronary%20Syndrome/">CAD</a> given negative outcomes in OPTIME-HF trial.</li>
<li>Most beneficial in nonischemic CM.</li>
<li>Potentially negative mortality benefit compared to nitroglycerin/nesiritide.</li>
</ul>
<h2 id="isoproterenol">Isoproterenol</h2>
<p>Isoproterenol is a potent, nonselective, synthetic β-adrenergic agonist with very low affinity for α-adrenergic receptors.</p>
<ul>
<li>powerful chronotropic and inotropic properties</li>
<li>potent systemic and mild pulmonary vasodilatory effects</li>
<li>stimulatory impact on stroke volume is counterbalanced by a β2-mediated drop in SVR, which results in a net neutral impact on CO.</li>
</ul>
<h2 id="dopamine">Dopamine</h2>
<p>Dopamine, an endogenous central neurotransmitter, is the immediate precursor to <a href="../Vasopressors/">norepinephrine</a> in the catecholamine synthetic pathway.</p>
<ul>
<li><strong>Pharmacokinetics:</strong> Half-life 2-3 minutes, metabilized by MAO and COMT.</li>
<li><strong>MOA:</strong>
    1) D1/2 receptor agonism at lowest doses (0.5-2 mcg/kg/min) which causes vasodilation in coronary, renal, mesenteric, and cerebral beds. Also causes natriuresis via renal tubular action.
    2) Predominantly weak beta-1 agonism at low doses (2-10 mcg/kg/min) which promotes norepinephrine release.
    3) Increasing alpha1-mediated vasoconstriction as dose escalates (&gt;10 mcg/kg/min). </li>
<li><strong>Dosing:</strong>
    1) 1-5 mcg/kg/min IV (low dose)  "renal dosing"
    2) 5-15 mcg/kg/min IV (medium dose)  "inotrope"
    3) 20-50 mcg/kg/min IV (high dose) "vasopressor"</li>
<li><strong>Caution:</strong> arrhythmogenic at the highest doses. Increases myocardial oxygen demands. No evidence for any renoprotective effects.</li>
</ul>
<p><img alt="" src="../_attachments/16ff3.jpg" /></p>
<h2 id="levosimendan">Levosimendan</h2>
<p>Not routinely available in Canada or the USA.</p>
<h2 id="evidence-base">Evidence Base</h2>
<h3 id="doremi-nejm-2021">DOREMI (NEJM 2021)</h3>
<p><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2026845">Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock | NEJM</a></p>
<ul>
<li><strong>Question:</strong> Is milrinone safer or more effective than dobutamine in the treatment of cardiogenic shock?</li>
<li><strong>Design:</strong> Single-centre blinded, 1:1 randomized and controlled, superiority trial</li>
<li><strong>Population:</strong> Consecutive adult patients admitted to the Ottawa CCU with cardiogenic shock (SCAI Stage B, C, D, E).</li>
<li><strong>Intervention:</strong> Milrinone (blinded)</li>
<li><strong>Comparator:</strong> Dobutamine (blinded)</li>
<li><strong>Outcomes:</strong> <ul>
<li>Primary: Composite of in-hospital mortality, resuscitated IHCA, cardiac transplant or MCS, nonfatal <a href="../../../Cardiology/Ischemic%20Heart%20Disease/Thrombotic%20Disease/ACS/">MI</a>, TIA/stroke, RRT</li>
</ul>
</li>
<li><strong>Results:</strong><ul>
<li>N=192. Primary outcome: <em>49% vs 54%</em> (RR 0.90, P=0.47). No difference in subgroups, time-to-event analysis</li>
<li>Secondary outcomes: No differences in sub-primaries, CCU LOS, hospital LOS, NIV, invasive ventilation, AKI, biochemistry, arrhythmias, dose of other <a href="../Vasopressors/">Vasopressors</a>.</li>
</ul>
</li>
<li><strong>Takeaway:</strong><ul>
<li>No significant advantage of milrinone over dobutamine. Trend towards slightly reduced primary outcome. No differences in safety profile</li>
<li><em>Underpowered study with some bias, and cannot rule out milrinone being better. For now, use either one -- whichever you are more comfortable with.</em></li>
</ul>
</li>
</ul>
<h2 id="references">References</h2>
<ol>
<li><a href="https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.107.728840">Inotropes and Vasopressors | Circulation</a></li>
<li><a href="https://www.uptodate.com/contents/use-of-vasopressors-and-inotropes">Use of vasopressors and inotropes - UpToDate</a></li>
<li><a href="https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-021-00806-8">Current use of inotropes in circulatory shock | Annals of Intensive Care | Full Text</a></li>
<li><a href="https://www.sciencedirect.com/science/article/pii/S0167527319325021">A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus - ScienceDirect</a></li>
<li><a href="https://www.cfrjournal.com/articles/inotropes-acute-heart-failure-guidelines-practical-use-therapeutic-options-and-clinical">Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice | CFR Journal</a></li>
<li><a href="https://www.uptodate.com/contents/inotropic-agents-in-heart-failure-with-reduced-ejection-fraction">Inotropic agents in heart failure with reduced ejection fraction - UpToDate</a></li>
<li><a href="https://derangedphysiology.com/main/required-reading/pharmacology-and-toxicology/Chapter%201.3.2/comparative-pharmacology-inotropes-and-vasopressors">Comparative pharmacology of inotropes and vasopressors | Deranged Physiology</a></li>
</ol>

  <br>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Massive%20Transfusion/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Massive%20Transfusion/" class="btn btn-xs btn-link">
        Massive Transfusion
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Fluid%20Responsiveness/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Fluid%20Responsiveness/" class="btn btn-xs btn-link">
        Fluid Responsiveness
      </a>
    </div>
    
  </div>

    <br>
</div>

<footer class="container-fluid wm-page-content">
  <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a> using <a href="https://github.com/gristlabs/mkdocs-windmill">Windmill</a> theme by Grist Labs.</p>
</footer>

</body>
</html>